ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Population Dynamic Projections of Near Vision Loss and Refractive Disorders in China and the G20 From 1990 to 2038.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Near vision loss (NVL) and refractive disorders (RD) are vision impairments that impact quality of life and economic factors globally. Public health planning requires understanding their burdens and predicting trends. MATERIAL AND METHODS Using Global Burden of Disease (GBD) 2021 data, we analyzed age-standardized prevalence rates (ASPR) and disability-adjusted life year rates (ASDR) for China and the G20 from 1990 to 2021. Trends were described using actual and estimated annual percentage changes. Bayesian age-period-cohort modeling predicted disease burden from 2022 to 2038. Decomposition analysis quantified contributions from population growth, aging, and epidemiological changes. RESULTS NVL ASPR in China was 40 341.49 per 100 000, higher than in the G20. RD ASPR in China was 3044.90 per 100 000, lower than in the G20. Both conditions were more prevalent among women. NVL burden was highest in the 55 to 64 age group; RD burden peaked in the 80 to 84 age group. Overall, NVL showed an increasing trend (China: +1.95%; G20: +1.92%); RD showed a decreasing trend (China: -0.46%; G20: -0.36%). NVL burden is projected to continue rising, whereas RD burden will decline by 2038; both are mainly influenced by population growth. CONCLUSIONS We identified divergent trends for NVL and RD in China and the G20 among adults. NVL burden has increased since the mid-1990s and is projected to continue rising through 2038; RD rates have declined. Burdens remain higher in women, particularly in middle-aged (NVL) and older (RD) populations. These findings support sustained, demographically responsive eye health planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.